BACKGROUND: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either colchicine or placebo and either spironolactone or placebo. The results of the colchicine trial are reported here. The primary efficacy outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization, evaluated in a time-to-event analysis. C-reactive protein was measured at 3 months in a subgroup of patients, and safety was also assessed. RESULTS: A total of 7062 patients at 104 centers in 14 countries underwent randomization; at the time of analysis, the vital status was unknown for 45 patients (0.6%), and this information was most likely missing at random. A primary-outcome event occurred in 322 of 3528 patients (9.1%) in the colchicine group and 327 of 3534 patients (9.3%) in the placebo group over a median follow-up period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.16; P = 0.93). The incidence of individual components of the primary outcome appeared to be similar in the two groups. The least-squares mean difference in C-reactive protein levels between the colchicine group and the placebo group at 3 months, adjusted according to the baseline values, was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a higher percentage of patients with colchicine than with placebo (10.2% vs. 6.6%; P<0.001), but the incidence of serious infections did not differ between groups. CONCLUSIONS: Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).

• MeSH
• C-reaktivní protein * analýza   MeSH
• cévní mozková příhoda prevence a kontrola   MeSH
• dvojitá slepá metoda MeSH
• infarkt myokardu * prevence a kontrola   mortalita   MeSH
• Kaplanův-Meierův odhad MeSH
• kolchicin * terapeutické užití   škodlivé účinky   MeSH
• lidé středního věku MeSH
• lidé MeSH
• recidiva MeSH
• sekundární prevence MeSH
• senioři MeSH
• spironolakton terapeutické užití   škodlivé účinky   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH

Systematic strategies for preventing and treating esophagogastric variceal rebleeding (EVRB) are currently inadequate. This systematic review aimed to update this critical gap by searching contemporary studies from major guideline websites, databases, and professional associations focused on EVRB prevention in cirrhosis patients. Key findings highlight evaluation methods, risk management, preventive measures, health education, and follow-up strategies. Notably, a hepatic venous pressure gradient exceeding 18 mmHg is identified as a reliable predictor of gastroesophageal varices (GOV) rebleeding. Effective management of primary diseases is crucial, with methods including antiviral and anti-fibrotic therapies, alcohol avoidance, vaccination, and careful medication management. The combination of nonselective β-blockers (NSBBs) and endoscopic variceal ligation (EVL) is established as the gold standard for secondary EVRB prevention. For patients experiencing recurrent bleeding despite NSBBs and EVL, transjugular intrahepatic portosystemic shunt (TIPS) therapy is recommended. Surgical options, such as surgical shunt and devascularization, are advised for those unsuitable for endoscopic therapy or TIPS, particularly in Child-Pugh A and B patients unresponsive to treatment. Additionally, traditional Chinese medicine options, such as Fufang Biejia Ruangan Tablets, Fuzheng Huayu Capsules, and Anluo Huaxian Pills, have shown promise in improving hepatic fibrosis and GOV in cirrhotic patients. This review offers a comprehensive overview of current prevention and treatment strategies for EVRB, providing valuable insights for clinicians and healthcare professionals.

• MeSH
• ezofageální a žaludeční varixy * komplikace   MeSH
• gastrointestinální krvácení * etiologie   prevence a kontrola   MeSH
• jaterní cirhóza * komplikace   MeSH
• lidé MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• systematický přehled MeSH

OBJECTIVE: Ischemic complications account for significant patient morbidity following aneurysmal subarachnoid hemorrhage (aSAH). The Prevention and Treatment of Vasospasm with Clazosentan (REACT) study was designed to assess the safety and efficacy of clazosentan, an endothelin receptor antagonist, in preventing clinical deterioration due to delayed cerebral ischemia (DCI) in patients with aSAH. METHODS: REACT was a prospective, multicenter, randomized, double-blind, phase 3 study. Eligible patients had aSAH secured by surgical clipping or endovascular coiling, and had presented with thick and diffuse clot on admission CT scan. Patients were randomized (1:1 ratio) to 15 mg/hour intravenous clazosentan or placebo within 96 hours of the aSAH for up to 14 days, in addition to standard of care treatment including oral or intravenous nimodipine. The primary efficacy endpoint was the occurrence of clinical deterioration due to DCI up to 14 days after initiation of the study drug. The main secondary endpoint was the occurrence of clinically relevant cerebral infarction at day 16 after study drug initiation. Other secondary endpoints included clinical outcome assessed on the modified Rankin Scale (mRS) and the Glasgow Outcome Scale-Extended (GOSE) at week 12 post-aSAH. Imaging and clinical endpoints were centrally adjudicated. RESULTS: A total of 409 patients were randomized between February 2019 and May 2022 across 74 international sites. Three patients did not start study treatment and were not included in the analysis set. The occurrence of clinical deterioration due to DCI was 15.8% (32/202 patients) in the clazosentan group and 17.2% (35/204 patients) in the placebo group, and the difference was not statistically significant (relative risk reduction [RRR] 7.2%, 95% CI -42.6% to 39.6%, p = 0.734). A nonsignificant RRR of 34.1% (95% CI -21.3% to 64.2%, p = 0.177) was observed in clinically relevant cerebral infarcts treated with clazosentan (7.4%, 15/202) versus placebo (11.3%, 23/204). Rescue therapy was less frequently needed for patients treated with clazosentan compared to placebo (10.4%, 21/202 vs 18.1%, 37/204; RRR 42.6%, 95% CI 5.4%-65.2%). A nonsignificant relative risk increase of 25.4% (95% CI -10.7% to 76.0%, p = 0.198) was reported in the risk of poor GOSE and mRS scores with clazosentan (24.8%, 50/202) versus placebo (20.1%, 41/204) at week 12 post-aSAH. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS: Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 (ClinicalTrials.gov) EU clinical trial registration no.: 2018-000241-39 (clinicaltrialsregister.eu).

• MeSH
• dioxany * terapeutické užití   škodlivé účinky   MeSH
• dospělí MeSH
• dvojitá slepá metoda MeSH
• intrakraniální vazospazmus etiologie   prevence a kontrola   farmakoterapie   diagnostické zobrazování   MeSH
• ischemie mozku * prevence a kontrola   etiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• prospektivní studie MeSH
• pyridiny * terapeutické užití   škodlivé účinky   aplikace a dávkování   MeSH
• pyrimidiny * terapeutické užití   škodlivé účinky   aplikace a dávkování   MeSH
• senioři MeSH
• subarachnoidální krvácení * komplikace   diagnostické zobrazování   MeSH
• sulfonamidy * terapeutické užití   škodlivé účinky   aplikace a dávkování   MeSH
• tetrazoly * terapeutické užití   škodlivé účinky   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH

Cílem práce je na ojedinělém případu pacienta po nadstandardní operaci šedého zákalu s preventivní primární zadní cirkulární kasulorexi (PCCC, z angl. posterior continuous curvilinear capsulorhexis) prezentovat možný vznik proliferativní sekundární katarakty. Vzhledem k negativnímu vlivu na zrakové funkce bylo rozhodnuto o ošetření Nd:YAG laserem, které bylo úspěšné s použitím minimální energie ale s porušením přední hyaloidní membrány. Kazuistika 65letý muž podstoupil na našem pracovišti v roce 2020 nekomplikovanou operaci šedého zákalu obou očí, oboustranně s primární PCCC s implantací tenzního kroužku a umělé nitrooční čočky do pouzdra. V únoru 2023 byl na doporučení spádového očního lékaře vyšetřen na naší ambulanci pro snížení zrakové ostrosti vpravo. Dominantní bylo rozmazané vidění. Diagnóza proliferativní formy sekundární katarakty byla potvrzena a zdokumentována pomocí fotografie předního segmentu v retroiluminaci a předněsegmentového OCT (Optovue, Avanti RTVue XR). Pacient byl indikován k Nd:YAG laserové disrupci proliferací v prostoru PCCC na pravém oku. Návrat zrakové ostrosti k původnímu stavu byl potvrzením správné diagnózy. V literárním přehledu a v diskuzi je shrnuta aktuální problematika sekundární katarakty a použití primární PCCC. Závěr: Sekundární katarakta je hlavní dlouhodobou komplikací moderní chirurgie katarakty. Jednou z možných řešení je preventivní provedení jednoduché PCCC, která může být provázená ojedinělým selháním.

The aim of the study is to present the possible development of proliferative secondary cataracts in the unique case of a patient having undergone premium cataract surgery with preventive primary posterior continuous curvilinear capsulorhexis (PCCC). Due to the negative effect on visual functions, it was decided to treat the patient with an Nd:YAG laser, which was successful with minimal energy but resulted in damage to the anterior hyaloid membrane. Case report In 2020, a 65-year-old man underwent uncomplicated cataract surgery in both eyes at our clinic bilaterally with primary PCCC with implantation of a tension ring and an artificial intraocular lens into the capsule. In February 2023, on the recommendation of the area ophthalmologist, he was examined at our outpatient clinic due to a decrease of visual acuity in the right eye. Blurred vision predominated. A diagnosis of proliferative form of secondary cataract was confirmed and documented using a photo of the anterior segment in retroillumination and anterior segment OCT (Optovue, Avanti RTVue XR). The patient was indicated for Nd:YAG laser disruption by proliferation in the PCCC space in the right eye. The return of visual acuity to its original state confirmed the correct diagnosis. The literature review and discussion summarize the current issue of secondary cataracts and the use of primary PCCC. Conclusion: Secondary cataract is the main long-term complication of modern cataract surgery. One of the possible solutions is the preventive implementation of a simple PCCC, which may be accompanied by isolated failure.

• MeSH
• capsulorhexis * metody   škodlivé účinky   MeSH
• extrakce katarakty metody   škodlivé účinky   MeSH
• implantace nitrooční čočky MeSH
• katarakta etiologie   MeSH
• lasery pevnolátkové terapeutické užití   MeSH
• lidé MeSH
• senioři MeSH
• zkalení zadního pouzdra čočky diagnóza   etiologie   MeSH
• zraková ostrost MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• kazuistiky MeSH

Extra-intrakraniální bypass představuje kontroverzní, ale významnou součást neurochirurgické léčby cerebrovaskulárních onemocnění. Indikacemi jsou nemoc moyamoya, stenookluzivní aterosklerotická choroba vnitřní karotidy, akutní ischemická cévní mozková příhoda (CMP) a vzácně i komplexní aneuryzmata a tumory baze lební. Přestože historické studie přinesly smíšené výsledky a omezily jeho využití, moderní diagnostické a chirurgické techniky opět otevírají cestu k selektivnímu uplatnění bypassu u vysoce rizikových pacientů. Jednoznačnou indikací je vzácná nemoc moyamoya, kde je bypass prokázanou metodou vedoucí k prevenci ischemických nebo hemoragických CMP. U pacientů se symptomatickým chronickým uzávěrem vnitřní karotidy a vyčerpanou cerebrovaskulární rezervou bypass představuje možnou léčebnou modalitu, pokud je pečlivě indikován na základě komplexního specializovaného vyšetření. Emergentní bypass by měl být zvažován pro úzkou skupinu pacientů u akutní ischemické CMP při selhání nebo nemožnosti standardní léčby. Přes pokračující diskuzi je extra-intrakraniální bypass i nadále důležitou součástí cerebrovaskulární chirurgie. Klíčovým faktorem úspěchu je správná selekce pacientů a precizní mikrochirurgické provedení. Moderní přístupy a technologie umožňují snížit riziko komplikací a zvýšit efektivitu této intervence, čímž poskytují naději pacientům s jinak omezenými možnostmi léčby.

Extra-intracranial bypass represents a controversial yet significant component of neurosurgical treatment for cerebrovascular diseases. The indications are moyamoya disease, steno-occlusive atherosclerotic disease of the internal carotid artery, acute ischemic stroke, and, more rarely, complex intracranial aneurysms and skull base tumors. Although historical studies have yielded mixed results and limited its use, modern diagnostic and surgical techniques are reopening the path for selective application of bypass in high-risk patients. A clear indication is the rare moyamoya disease, where bypass is a proven method for preventing ischemic or hemorrhagic strokes. In patients with symptomatic chronic internal carotid artery occlusion and exhausted cerebrovascular reserve, bypass may serve as a potential treatment modality, provided it is carefully indicated through comprehensive specialized evaluation. Emergent bypass should be considered for a narrow group of patients with acute ischemic stroke when standard treatment fails or is not feasible. Despite ongoing debate, extra-intracranial bypass remains an essential part of cerebrovascular surgery. The key to success lies in the proper selection of patients and precise microsurgical execution. Modern approaches and technologies help reduce the risk of complications and enhance the effectiveness of this intervention, offering hope to patients with otherwise limited treatment options.

• MeSH
• cerebrovaskulární poruchy * chirurgie   MeSH
• lidé MeSH
• moyamoya nemoc chirurgie   patologie   MeSH
• neurochirurgické výkony MeSH
• revaskularizace mozku * metody   MeSH
• Check Tag
• lidé MeSH

BACKGROUND: Solid organ transplant recipients (SOTRs) face higher cancer risk because of immunosuppressive therapy used to prevent organ rejection. We hypothesized that SOTRs treated with radical cystectomy (RC) and pelvic lymph-node dissection (PLND) for bladder cancer (UBC) might have worse survival outcomes compared to non-SOTRs. This study aims to assess survival outcomes of SOTRs treated with RC and PLND for UBC compared to non-SOTRs. METHODS: A retrospective analysis of 645 patients treated with RC and PLND for UBC, originating from our multicenter cooperation program (2002-2022), stratified in two groups according to previous solid organ transplantation. Co-primary endpoints were OS and CSS, assessed using mixed-effects Cox-analysis. Secondary endpoints included postoperative complications, readmission-rates, operation time, estimated blood loss and length of stay. RESULTS: Of the 361 patients analyzed (median follow-up: 17 months), 23 were SOTRs. SOTRs exhibited lower 12-month (70% vs. 80%) and 24-month (36% vs. 68%) OS-rates compared to non-SOTRs (P=0.011). Corresponding CSS-rates were also lower for SOTRs at 12 (81% vs. 85%) and 24 months (55% vs. 76%) (P=0.016). Multivariable Cox-regression identified a prior solid organ transplant (OR:5.2; P=0.002), higher pathologic-stage (OR:3.8; P=0.03 for pT2, OR:3.6; P=0.04 for pT3, OR:4.5; P=0.03 for pT4), and administration of "any systemic treatment" (OR:0.3; P=0.001) as OS predictors. For CSS, predictors were a prior solid organ transplant (OR:3.0; P=0.03), higher pathologic-stage (OR:9.8; P=0.04 for pT3, OR:13; P=0.02 for pT4), and administration of "any systemic treatment" (OR:0.4; P=0.03). CONCLUSIONS: Solid organ transplant recipients undergoing RC and PLND for urinary UBC have worse survival outcomes compared to non-SOTRs. Our findings may impact patient counseling, follow-up, and planning future clinical trials.

• MeSH
• cystektomie * metody   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lymfadenektomie MeSH
• míra přežití MeSH
• nádory močového měchýře * chirurgie   mortalita   patologie   MeSH
• pooperační komplikace epidemiologie   MeSH
• příjemce transplantátu MeSH
• retrospektivní studie MeSH
• senioři MeSH
• transplantace orgánů * MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH

Improving the quality of the most basic health behavior among youth may contribute to short-term body composition management with long-term implications for noncommunicable disease regression. This investigation aimed to assess the impact of primary school physical activity (PA), dietary, or dual approach interventions on pupils' body weight (BW) and body mass index (BMI). A systematic review and meta-analysis was completed following a study protocol and a trial registration (PROSPERO: CRD4202347770) with the PRISMA approach. Publications in English or German were included with school-based randomized controlled trials on diet and/or PA. Pupils of primary schools (aged 5-10) with no major nutritional deficiency or unstable health condition were included. The Boolean search strategy revealed a total of 9479 articles, qualifying 39 studies with 20 462 pupils (including 10 211 girls and 10 251 boys) for quantitative synthesis. The interventions were mostly PA (n = 31), several were dietary (n = 6), and some were dual approach (n = 5). Random effects meta-analyses revealed PA intervention (n = 20) to have an effect size of +0.07 kg (95% CI: -0.01 to 0.15) and -0.12 kg/m2 (95% CI: -0.23 to -0.01). Low statistical heterogeneity was found for BW (I2 = 0%; P = 1.000) and BMI (I2 = 0%; P = .9688), respectively. The findings indicate a scarcity of top-quality scientific research performed on healthy diet for body weight management in primary schools. PA intervention for elementary school pupils provides support for a healthier body composition profile amidst the current world health crisis.

• MeSH
• cvičení * MeSH
• dieta * MeSH
• dítě MeSH
• index tělesné hmotnosti MeSH
• lidé MeSH
• podpora zdraví * metody   MeSH
• předškolní dítě MeSH
• randomizované kontrolované studie jako téma MeSH
• školní zdravotnické služby MeSH
• školy MeSH
• studenti * statistika a číselné údaje   MeSH
• tělesná hmotnost * MeSH
• veřejné zdravotnictví * MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mužské pohlaví MeSH
• předškolní dítě MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• metaanalýza MeSH
• systematický přehled MeSH

Brožura je sborníkem prací, které se zaměřily na harm reduction prevenci nádorových nemocí. Určeno odborné veřejnosti.

• MeSH
• nádory prevence a kontrola   MeSH
• primární prevence MeSH
• sekundární prevence MeSH
• snížení rizika poškození MeSH
• Publikační typ
• sborníky MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• onkologie
• preventivní medicína
• NLK Publikační typ
• brožury

PURPOSE: A healthy lifestyle may prevent or mitigate late effects in childhood, adolescent and young adult (CAYA) cancer survivors. To support survivors in adopting healthier behaviours, the PanCareFollowUp (PCFU) Lifestyle intervention was developed, encompassing 4 months of online lifestyle coaching aimed at achieving a personal lifestyle goal. The aims of this study were to (1) determine the efficacy of this intervention on lifestyle outcomes over time and (2) identify predictors for goal achievement. PATIENTS AND METHODS: Fifty-eight survivors were enrolled. Outcomes were assessed at baseline (T0), after 4 months of coaching (T1) and after 4 months of follow-up (T2). The primary outcome included the percentage of survivors successful in achieving and sustaining their goal, whereas secondary outcomes included differences in body mass index (BMI), diet and physical activity. To evaluate the adjusted, longitudinal effects on secondary outcomes, linear mixed models were estimated. Predictors for goal achievement were identified through logistic regression analysis. RESULTS: At T1 and T2, 68% and 76% of goals were achieved or sustained, respectively. Mean differences between T2 and T0 showed significant improvements in BMI (-0.5 kg/m2), diet (-0.6 points) and physical activity (+7.7 h/week). Estimation of multivariable models also showed positive effects. Participants with a lower BMI and fewer depressive feelings at baseline were more likely to achieve and/or sustain their goals at T2. CONCLUSION: Findings suggest that the PCFU Lifestyle intervention supports survivors in making lifestyle changes. Results can be used to inform a subsequent randomised intervention study and integrate lifestyle coaching into care. TRIAL REGISTRATION: International Clinical Trial Registry Platform (ICTRP) number: NL8932 (ICTRP Search Portal [who. int]). Registered on 29 September 2020.

• MeSH
• cvičení * MeSH
• dítě MeSH
• dospělí MeSH
• index tělesné hmotnosti MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• nádory terapie   psychologie   MeSH
• přežívající onkologičtí pacienti * psychologie   MeSH
• telemedicína * MeSH
• zdravý životní styl MeSH
• životní styl MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

Inclisiran je zástupcem injekčních hypolipidemik, který cílí na potlačení syntézy enzymu proproteinové konvertázy subtilisinu/kexinu 9 (proprotein convertase subtilisin/kexin type 9, PCSK9) a tím snižuje koncentraci cholesterolu (především LDL [lipoproteiny o nízké hustotě, low density lipoprotein] cholesterolu) v krvi. Lze jej podávat jak v primární prevenci (u pacientů s familiární hypercholesterolemií), tak v prevenci sekundární. Kazuistika demonstruje účinnou léčbu inclisiranem u pacienta s ischemickou chorobou srdeční.

Inclisiran is a representative of injectable hypolipidemics, which aims to suppress the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby reducing the level of cholesterol (primarily LDL [low density lipoprotein] cholesterol) in blood. It can be administered both in primary prevention (in patients with familial hypercholesterolemia) and in secondary prevention. A case report demonstrates the effective treatment with inclisiran in a patient with ischemic heart disease.

• Klíčová slova
• inclisiran,
• MeSH
• cholesterol klasifikace   krev   MeSH
• dyslipidemie diagnóza   farmakoterapie   MeSH
• hypolipidemika * farmakologie   terapeutické užití   MeSH
• ischemická choroba srdeční diagnóza   farmakoterapie   prevence a kontrola   MeSH
• kardiovaskulární nemoci farmakoterapie   prevence a kontrola   MeSH
• lidé MeSH
• sekundární prevence metody   MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• kazuistiky MeSH
• práce podpořená grantem MeSH